ARDX Share Price Performance
US$4.33
-1.50 (-25.73%)
60.3% undervalued intrinsic discount
US$10.91
Fair Value
Price US$4.33
AnalystConsensusTarget US$10.91
Fair ValueUS$10.91
Share PriceUS$4.33
60.3% undervalued intrinsic discount
ARDX Community Narratives
AN
Fair Value US$10.91 60.3% undervalued intrinsic discount
Omnichannel Investments And Sales Teams Will Create Future IBSRELA Demand
0users have liked this narrative
0users have commented on this narrative
55users have followed this narrative
ARDX Community Fair Values
- AN
Consensus Narrative from 11 AnalystsOmnichannel Investments And Sales Teams Will Create Future IBSRELA Demand
Key Takeaways Strategic investments and an expanded sales team are expected to drive demand for IBSRELA, boosting revenue and market share. A strong cash reserve and pipeline development support future growth, aiming to enhance long-term profitability and earnings.US$10.91FV60.3% undervalued intrinsic discount22.89%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative55users have followed this narrative12 days ago author updated this narrative
Recent ARDX News & Updates
No updates
Ardelyx, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 04, 2025
- Earnings per share (EPS)
- -0.22
- Gross Margin
- 68.92%
- Net Profit Margin
- -14.86%
- Debt/Equity Ratio
- 122.1%
Ardelyx, Inc. Competitors
About ARDX
- Founded
- 2007
- Employees
- 395
- CEO
- WebsiteView website
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading